Expression of surface platelet receptors (CD62P and CD41/61) in horses with recurrent airway obstruction (RAO)

Iwaszko-Simonik, Alicja; Niedźwiedź, Artur; Graczyk, Stanisław; Słowikowska, Malwina; Pliszczak-Król, Aleksandra

doi:10.1016/j.vetimm.2015.01.002

Cited by 5 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous equine studies using flow cytometry demonstrated increased platelet activation in experimental settings after induced infection with equine infectious anemia virus 49 and in the course of carbohydrate-induced laminitis 71 ; results were inconsistent in studies of platelet activation in horses with antigen-induced equine asthma. 20 , 29 , 30 …”

Section: Discussionmentioning

confidence: 99%

“…Activated platelets and PLAs were measured by dual-labeling with conjugated antibodies (all Bio-Rad, formerly AbD Serotec) as described. 4 , 34 An allophycocyanin (APC)-conjugated (LYNX rapid antibody conjugation kit; Bio-Rad) monoclonal mouse anti-sheep antibody against CD41/61 with cross-reactivity against equine platelet CD41/61 7 , 29 , 30 was used as platelet marker (MCA1095GA, dilution 1:50 with modified HEPES/Tyrod buffer 4 ). Activation of platelets was determined with fluorescein isothiocyanate (FITC)-conjugated (LYNX rapid antibody conjugation kit; Bio-Rad) monoclonal mouse anti-human antibodies against CD62P (MCA2419, dilution 1:50 with modified HEPES/Tyrod buffer).…”

Section: Methodsmentioning

confidence: 99%

“…The anti-CD62P has been used successfully as a marker of equine platelet activation. 29 , 30 A FITC-conjugated monoclonal mouse anti-horse antibody against CD11a/18 (MCA1081F, dilution 1:200 with modified HEPES/Tyrod buffer) served as leukocyte marker. Matched isotype antibodies were used for negative controls: APC-conjugated polyclonal goat anti-mouse immunoglobulin (Ig) for measurements of CD41/61 expression (550826; Becton Dickinson), FITC-conjugated polyclonal goat anti-mouse Ig for CD62P (sc-2010; Santa Cruz), and FITC-conjugated polyclonal goat anti-mouse Ig for CD11a/18 (554001; Becton Dickinson).…”

Section: Methodsmentioning

confidence: 99%

“… 4 Anti-CD41/61 has been used as a specific platelet marker in equine studies, and platelet activation has been identified by increased expression of CD62P. 7 , 20 , 29 , 30 , 35 , 55 , 60 , 72 Equine leukocytes have been identified with antibodies against CD11a/18, CD13, and CD18. 7 , 20 , 35 Platelet activation has been measured in equine studies in PRP 7 , 30 , 35 , 55 , 60 , 70 and in centrifuged platelet-leukocyte-rich plasma (PLRP).…”

mentioning

confidence: 99%

“… 7 , 20 , 29 , 30 , 35 , 55 , 60 , 72 Equine leukocytes have been identified with antibodies against CD11a/18, CD13, and CD18. 7 , 20 , 35 Platelet activation has been measured in equine studies in PRP 7 , 30 , 35 , 55 , 60 , 70 and in centrifuged platelet-leukocyte-rich plasma (PLRP). 7 , 20 , 35 …”

mentioning

confidence: 99%

See 4 more Smart Citations

Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome

Theuerkauf¹,

Obach-Schröck

Staszyk

et al. 2022

J VET Diagn Invest

View full text Add to dashboard Cite

In humans, activated platelets contribute to sepsis complications and to multiple organ failure. In our prospective analytical study of cases of the equine systemic inflammatory response syndrome (SIRS), we adapted a standard human protocol for the measurement of activated platelets and platelet-leukocyte aggregates (PLAs) in equine platelet-leukocyte-rich plasma (PLRP) by flow cytometry, and we investigated the hypothesis that activated platelets and PLAs are increased in clinical cases of SIRS. We included 17 adult horses and ponies fulfilling at least 2 SIRS criteria, and 10 healthy equids as controls. Activation of platelets was determined by increased expression of CD62P on platelets. Activated platelets and PLAs were measured before and after in vitro activation of platelets with collagen. Median expression of CD62P on platelets was significantly increased after activation in the control group: 1.45% (interquartile range [IQR]: 1.08–1.99%) initially versus 8.78% (IQR: 6.79–14.78%, p = 0.002) after activation. The equids with SIRS had significantly more activated platelets and PLAs in native PLRP than controls: CD62P 4.92% (median, IQR: 2.21–12.41%) versus 1.45% in controls (median, IQR: 1.08–1.99%, p = 0.0007), and PLAs 4.16% (median, IQR: 2.50–8.58%) versus 2.95% in controls (median, IQR: 1.57–3.22%, p = 0.048). To our knowledge, increased platelet activation and PLAs have not been demonstrated previously with flow cytometry in clinical cases of equine SIRS.

show abstract